筛选条件 共查询到154条结果
排序方式
CDK19 regulates the proliferation of hematopoietic stem cells and acute myeloid leukemia cells by suppressing p53-mediated transcription of p21

期刊: LEUKEMIA, 2022; 36 (4)

The cell cycle progression of hematopoietic stem cells (HSCs) and acute myeloid leukemia (AML) cells is precisely controlled by multiple regulatory fa......

JIF:8.214

Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway

期刊: LEUKEMIA, 2022; 36 (2)

Regulatory T cells (Tregs) could maintain the characteristics of stem cells and inhibit the differentiation of normal hematopoietic stem/progenitor ce......

JIF:8.214

SETD5 modulates homeostasis of hematopoietic stem cells by mediating RNA Polymerase II pausing in cooperation with HCF-1

期刊: LEUKEMIA, 2022; 36 (4)

SETD5 mutations were identified as the genetic causes of neurodevelopmental disorders. While the whole-body knockout of Setd5 in mice leads to embryon......

JIF:8.214

Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis

期刊: LEUKEMIA, 2022; 36 (6)

Langerhans cell histiocytosis (LCH) is a clonal histiocytic neoplasm with various clinical manifestations and heterogeneous prognoses. No standard the......

JIF:8.214

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis

期刊: LEUKEMIA, 2022; 36 (11)

C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, which can be considered as......

JIF:8.214

Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy

期刊: LEUKEMIA, 2022; 36 (8)

It is vital for physicians and persons with chronic myeloid leukemia (CML) to accurately predict the likelihood of achieving a major molecular respons......

JIF:8.214

MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma

期刊: LEUKEMIA, 2022; 36 (7)

Anthracycline-based chemotherapy resistance represents a major challenge in diffuse large B-cell lymphoma (DLBCL). MiRNA and gene expression profiles ......

JIF:8.214

Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction

期刊: LEUKEMIA, 2022; 36 (11)

Chimeric antigen receptor T cells (CAR-T) therapy has achieved remarkable therapeutic success in treating a variety of hematopoietic malignancies. How......

JIF:8.214

Insufficiency of FZR1 disturbs HSC quiescence by inhibiting ubiquitin-dependent degradation of RUNX1 in aplastic anemia

期刊: LEUKEMIA, 2022; 36 (3)

FZR1 has been implicated as a master regulator of the cell cycle and quiescence, but its roles and molecular mechanisms in the pathogenesis of severe ......

JIF:8.214

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial

期刊: LEUKEMIA, 2022; 36 (1)

Increasing the remission rate and reducing the recurrence rate can improve the clinical efficacy of chimeric antigen receptor (CAR) T cell therapy in ......

JIF:8.214

3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia

期刊: LEUKEMIA, 2022; 36 (1)

Sphingolipids and their metabolic pathways have been implicated in disease development and therapeutic response; however, the detailed mechanisms rema......

JIF:8.214

Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial

期刊: LEUKEMIA, 2022; 36 (5)

Some patients with acquired pure red cell aplasia (aPRCA) have no response or are intolerant to cyclosporine A. From April 2017 to August 2020, patien......

JIF:8.214

共154条页码: 1/11页15条/页